

ESPS PEER-REVIEW REPORT

Name of journal: World Journal of Clinical Oncology

ESPS manuscript NO: 21856

Title: Neoadjuvant therapy for gastroesophageal adenocarcinoma

Reviewer's code: 02519698

Reviewer's country: United States

Science editor: Yue-Li Tian

Date sent for review: 2015-07-31 09:39

Date reviewed: 2015-08-03 01:56

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input checked="" type="checkbox"/> Grade A: Priority publishing	Google Search:	<input type="checkbox"/> Accept
<input checked="" type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Duplicate publication	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	<input checked="" type="checkbox"/> No	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor		BPG Search:	<input checked="" type="checkbox"/> Major revision
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		<input checked="" type="checkbox"/> No	

COMMENTS TO AUTHORS

Overall good review with some comments and suggestions below:

1. Abstract: clearly chemoradiation without surgery is potentially curative for esophageal cancer (as proven by 2 randomized trials looking at chemoRT +/- surgery, including FFCD trial referenced in text). Stating that surgery is necessary for cure for both esophageal and gastric cancers is not accurate or appropriate. If you want to make this assertion, please limit the discussion to gastric cancers, specifically Siewert III only.
2. Abstract: citing MAGIC trial for esophageal cancer doesn't particularly make sense. Please reference the POET trial looking at the importance of radiotherapy for GE junction cancer.
3. Introduction: again surgery is not the only curative treatment for esophageal cancers
4. Adjuvant therapies: Please discuss any data comparing chemotherapy alone vs. chemoRT - ie., POET trial for GE junction cancer. Please comment why the INT-0116 (MacDonald trial) had a higher numerical 5 year survival than the MAGIC trial for gastric cancer. Please discuss metaanalyses comparing induction chemotherapy vs. chemoRT for esophageal cancer. Finally, please comment on why the absolute survival advantage for chemotherapy alone in the metaanalyses was ~6% while the CROSS trial had a more robust 13% survival advantage.
- 5)



BAISHIDENG PUBLISHING GROUP INC

8226 Regency Drive, Pleasanton, CA 94588, USA

Telephone: +1-925-223-8242

Fax: +1-925-223-8243

E-mail: bpgoffice@wjgnet.com

<http://www.wjgnet.com>

Conclusions: I might be biased but it appears that trimodality therapy is superior to bimodality therapy. However, I completely agree that intensifying chemotherapy in chemoRT regimens makes intuitive sense - but needs to be validated in randomized trials. You should acknowledge that CALGB 80101 tried this but failed. Also comment on Her-2/neu inhibitors. Again great job overall! I would actually suggest including one of your radiotherapy colleagues to this manuscript.



BAISHIDENG PUBLISHING GROUP INC

8226 Regency Drive, Pleasanton, CA 94588, USA

Telephone: +1-925-223-8242

Fax: +1-925-223-8243

E-mail: bpgoffice@wjgnet.com

http://www.wjgnet.com

ESPS PEER-REVIEW REPORT

Name of journal: World Journal of Clinical Oncology

ESPS manuscript NO: 21856

Title: Neoadjuvant therapy for gastroesophageal adenocarcinoma

Reviewer's code: 00181388

Reviewer's country: Iran

Science editor: Yue-Li Tian

Date sent for review: 2015-07-31 09:39

Date reviewed: 2015-08-23 04:48

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B: Very good	<input checked="" type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> High priority for publication
<input checked="" type="checkbox"/> Grade C: Good		<input type="checkbox"/> Duplicate publication	
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Plagiarism	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade E: Poor	<input type="checkbox"/> Grade D: Rejected	<input checked="" type="checkbox"/> No	<input checked="" type="checkbox"/> Minor revision
		BPG Search:	<input type="checkbox"/> Major revision
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		<input checked="" type="checkbox"/> No	

COMMENTS TO AUTHORS

There are some review, systematic review and meta-analysis about therapy for gastroesophageal adenocarcinoma. Authors can refer to some of these papers in their manuscript instead of referring to trilas when we have some updated reports in review articles.



BAISHIDENG PUBLISHING GROUP INC

8226 Regency Drive, Pleasanton, CA 94588, USA

Telephone: +1-925-223-8242

Fax: +1-925-223-8243

E-mail: bpgoffice@wjgnet.com

http://www.wjgnet.com

ESPS PEER-REVIEW REPORT

Name of journal: World Journal of Clinical Oncology

ESPS manuscript NO: 21856

Title: Neoadjuvant therapy for gastroesophageal adenocarcinoma

Reviewer's code: 02445418

Reviewer's country: Greece

Science editor: Yue-Li Tian

Date sent for review: 2015-07-31 09:39

Date reviewed: 2015-08-23 16:51

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input checked="" type="checkbox"/> Grade A: Excellent	<input checked="" type="checkbox"/> Grade A: Priority publishing	Google Search:	<input checked="" type="checkbox"/> Accept
<input type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C: Good		<input type="checkbox"/> Duplicate publication	
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Plagiarism	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade E: Poor	<input type="checkbox"/> Grade D: Rejected	<input checked="" type="checkbox"/> No	<input type="checkbox"/> Minor revision
		BPG Search:	<input type="checkbox"/> Major revision
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		<input checked="" type="checkbox"/> No	

COMMENTS TO AUTHORS

Very well done